Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RCOR - Renovacor Inc

Previous close
3.2
0   0%

Share volume: 2,031
Last Updated: Wed 30 Nov 2022 06:00:00 AM CET
Biological Product (except Diagnostic) Manufacturing : -3.41%

PREVIOUS CLOSE
CHG
CHG%
$3.20
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
76%
Profitability 93%
Dept financing 25%
Liquidity 0%
Performance 90%
Performance
5 Days
7.93%
1 Month
4.92%
3 Months
81.82%
6 Months
53.11%
1 Year
-62.88%
2 Year
-67.74%
Key data
Stock price
$3.20
P/E Ratio 
0.00
DAY RANGE
$3.20 - $3.20
EPS 
$0.00
52 WEEK RANGE
$1.34 - $9.74
52 WEEK CHANGE
-$0.63
MARKET CAP 
55.262 M
YIELD 
N/A
SHARES OUTSTANDING 
17.269 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$23,965
AVERAGE 30 VOLUME 
$26,286
Company detail
CEO:
Region: US
Website: renovacor.com
Employees: 2
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing

Renovacor is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor’s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.

Recent news